Market Cap
US$1.1b
Last Updated
2020/02/17 00:41 UTC
Data Sources
Company Financials +
Executive Summary
CareDx, Inc., a transplant diagnostics company, together with its subsidiaries, focuses on the discovery, development, and commercialization of diagnostic solutions for transplant patients worldwide.
Rewards
Risk Analysis
Snowflake Analysis
High growth potential with excellent balance sheet.
Similar Companies
Share Price & News
How has CareDx's share price performed over time and what events caused price changes?
Latest Share Price and Events
Stable Share Price: CDNA's share price has been volatile over the past 3 months.
Market Performance
7 Day Return
9.8%
CDNA
-0.5%
US Biotechs
1.5%
US Market
1 Year Return
0.6%
CDNA
11.0%
US Biotechs
20.1%
US Market
Return vs Industry: CDNA underperformed the US Biotechs industry which returned 11% over the past year.
Return vs Market: CDNA underperformed the US Market which returned 20.1% over the past year.
Shareholder returns
| CDNA | Industry | Market | |
|---|---|---|---|
| 7 Day | 9.8% | -0.5% | 1.5% |
| 30 Day | 13.0% | 0.6% | 1.4% |
| 90 Day | 32.1% | 9.3% | 8.7% |
| 1 Year | 0.6%0.6% | 12.0%11.0% | 22.7%20.1% |
| 3 Year | 1059.6%1059.6% | 16.9%13.6% | 50.1%40.5% |
| 5 Year | 334.4%334.4% | -1.5%-6.2% | 73.1%54.1% |
Price Volatility Vs. Market
How volatile is CareDx's share price compared to the market and industry in the last 5 years?
Simply Wall St News
2 weeks ago | Simply Wall St
How CareDx, Inc (NASDAQ:CDNA) Can Impact Your Portfolio Volatility1 month ago | Simply Wall St
We Think CareDx (NASDAQ:CDNA) Can Easily Afford To Drive Business Growth1 month ago | Simply Wall St
Should You Worry About CareDx, Inc's (NASDAQ:CDNA) CEO Salary Level?Valuation
Is CareDx undervalued compared to its fair value and its price relative to the market?
11.6x
Price to Book (PB) ratio
Share Price vs. Fair Value
Below Fair Value: CDNA ($26.67) is trading above our estimate of fair value ($12.54)
Significantly Below Fair Value: CDNA is trading above our estimate of fair value.
Price To Earnings Ratio
PE vs Industry: CDNA is unprofitable, so we can't compare its PE Ratio to the Biotechs industry average.
PE vs Market: CDNA is unprofitable, so we can't compare its PE Ratio to the US market.
Price to Earnings Growth Ratio
PEG Ratio: Insufficient data to calculate CDNA's PEG Ratio to determine if it is good value.
Price to Book Ratio
PB vs Industry: CDNA is overvalued based on its PB Ratio (11.6x) compared to the US Biotechs industry average (3.2x).
Next Steps
Future Growth
How is CareDx forecast to perform in the next 1 to 3 years based on estimates from 5 analysts?
86.8%
Forecasted annual earnings growth
Earnings and Revenue Growth Forecasts
Analyst Future Growth Forecasts
Earnings vs Savings Rate: CDNA is forecast to become profitable over the next 3 years, which is considered faster growth than the savings rate (1.7%).
Earnings vs Market: CDNA is forecast to become profitable over the next 3 years, which is considered above average market growth.
High Growth Earnings: CDNA's is expected to become profitable in the next 3 years.
Revenue vs Market: CDNA's revenue (33.4% per year) is forecast to grow faster than the US market (7.6% per year).
High Growth Revenue: CDNA's revenue (33.4% per year) is forecast to grow faster than 20% per year.
Earnings per Share Growth Forecasts
Future Return on Equity
Future ROE: Insufficient data to determine if CDNA's Return on Equity is forecast to be high in 3 years time
Next Steps
Past Performance
How has CareDx performed over the past 5 years?
-35.4%
Historical annual earnings growth
Earnings and Revenue History
Quality Earnings: CDNA is currently unprofitable.
Growing Profit Margin: CDNA is currently unprofitable.
Past Earnings Growth Analysis
Earnings Trend: CDNA is unprofitable, and losses have increased over the past 5 years at a rate of -35.4% per year.
Accelerating Growth: Unable to compare CDNA's earnings growth over the past year to its 5-year average as it is currently unprofitable
Earnings vs Industry: CDNA is unprofitable, making it difficult to compare its past year earnings growth to the Biotechs industry (66.2%).
Return on Equity
High ROE: CDNA has a negative Return on Equity (-21.47%), as it is currently unprofitable.
Return on Assets
Return on Capital Employed
Next Steps
Financial Health
How is CareDx's financial position?
Financial Position Analysis
Short Term Liabilities: CDNA's short term assets ($68.1M) exceed its short term liabilities ($31.0M).
Long Term Liabilities: CDNA's short term assets ($68.1M) exceed its long term liabilities ($16.3M).
Debt to Equity History and Analysis
Debt Level: CDNA is debt free.
Reducing Debt: CDNA has no debt compared to 5 years ago when its debt to equity ratio was 31%.
Balance Sheet
Inventory Level: CDNA has a low level of unsold assets or inventory.
Debt Coverage by Assets: CDNA's debt is covered by short term assets (assets are 1.5340161050749E+17x debt).
Cash Runway Analysis
For companies that have on average been loss making in the past we assess whether they have at least 1 year of cash runway.
Stable Cash Runway: CDNA has sufficient cash runway for more than 3 years based on its current free cash flow.
Forecast Cash Runway: Insufficient data to determine if CDNA has enough cash runway if its free cash flow continues to grow or shrink based on historical rates.
Next Steps
Dividend
What is CareDx's current dividend yield, its reliability and sustainability?
Dividend Yield vs Market
Current dividend yield vs market & industry
Notable Dividend: Unable to evaluate CDNA's dividend yield against the bottom 25% of dividend payers, as the company has not reported any payouts.
High Dividend: Unable to evaluate CDNA's dividend yield against the top 25% of dividend payers, as the company has not reported any payouts.
Stability and Growth of Payments
Stable Dividend: Insufficient data to determine if CDNA's dividends per share have been stable in the past.
Growing Dividend: Insufficient data to determine if CDNA's dividend payments have been increasing.
Current Payout to Shareholders
Dividend Coverage: Insufficient data to calculate payout ratio to determine if its dividend payments are covered by earnings.
Future Payout to Shareholders
Future Dividend Coverage: No need to calculate the sustainability of CDNA's dividend in 3 years as they are not forecast to pay a notable one for the US market.
Next Steps
Management
How experienced are the management team and are they aligned to shareholders interests?
2.8yrs
Average management tenure
CEO
Peter Maag (52yo)
7.3yrs
Tenure
US$5,231,391
Compensation
Dr. Peter Maag, PhD has been the Chief Executive Officer of CareDx, Inc. since October 2012 and Chairman of the Board since January 1, 2020. He was its President since October 2012 until November 26, 2018. ...
CEO Compensation Analysis
Compensation vs Market: Peter's total compensation ($USD5.23M) is above average for companies of similar size in the US market ($USD2.47M).
Compensation vs Earnings: Peter's compensation has increased whilst the company is unprofitable.
Leadership Team
| Name | Position | Tenure | Compensation | Ownership |
|---|---|---|---|---|
| Chairman & CEO | 7.3yrs | US$5.23m | 0.46% $5.3m | |
| President & Chief Business Officer | 1.3yrs | US$3.55m | 0.020% $223.1k | |
| Chief Financial Officer | 2.8yrs | US$2.10m | 0.027% $305.1k | |
| Chief Medical Officer | 13.5yrs | US$697.50k | 0.049% $554.6k | |
| Chief Commercial Officer | 2.7yrs | no data | 0.0045% $50.5k |
2.8yrs
Average Tenure
50yo
Average Age
Experienced Management: CDNA's management team is considered experienced (2.8 years average tenure).
Board Members
| Name | Position | Tenure | Compensation | Ownership |
|---|---|---|---|---|
| Chairman & CEO | 7.3yrs | US$5.23m | 0.46% $5.3m | |
| Independent Director | 17.1yrs | US$242.95k | 0.16% $1.8m | |
| Lead Independent Director | 0.08yrs | US$328.67k | 0.21% $2.4m | |
| Independent Director | 14.8yrs | US$255.38k | 0.15% $1.7m | |
| Independent Director | 4.9yrs | US$245.37k | 0.030% $340.7k | |
| Member of Advisory Board | 0yrs | no data | no data | |
| Member of Advisory Board | 0yrs | no data | no data | |
| Member of Advisory Board | 0yrs | no data | no data | |
| Independent Director | 5.8yrs | US$257.32k | 0.22% $2.5m | |
| Director | 0.6yrs | no data | 0.011% $127.4k |
4.9yrs
Average Tenure
63yo
Average Age
Experienced Board: CDNA's board of directors are considered experienced (4.9 years average tenure).
Ownership
Who are the major shareholders and have insiders been buying or selling?
Insider Trading Volume
Insider Buying: CDNA insiders have only sold shares in the past 3 months.
Recent Insider Transactions
Ownership Breakdown
Dilution of Shares: Shareholders have been diluted in the past year, with total shares outstanding growing by 27.5%.
Top Shareholders
Company Information
CareDx, Inc's company bio, employee growth, exchange listings and data sources
Key Information
- Name: CareDx, Inc
- Ticker: CDNA
- Exchange: NasdaqGM
- Founded: 1998
- Industry: Biotechnology
- Sector: Pharmaceuticals & Biotech
- Market Cap: US$1.132b
- Shares outstanding: 42.44m
- Website: https://www.caredx.com
Number of Employees
Location
- CareDx, Inc
- 3260 Bayshore Boulevard
- Brisbane
- California
- 94005
- United States
Listings
| Ticker | Exchange | Primary Security | Security Type | Country | Currency | Listed on |
|---|---|---|---|---|---|---|
| CDNA | NasdaqGM (Nasdaq Global Market) | Yes | Common Stock | US | USD | Jul 2014 |
| 1K9 | DB (Deutsche Boerse AG) | Yes | Common Stock | DE | EUR | Jul 2014 |
Biography
CareDx, Inc., a transplant diagnostics company, together with its subsidiaries, focuses on the discovery, development, and commercialization of diagnostic solutions for transplant patients worldwide. The company develops and provides a diagnostic surveillance testing solution for heart and kidney transplant recipients. It offers AlloMap, a heart transplant molecular test; and AlloSure, a donor-derived cell-free DNA test initially used for kidney transplant patients. The company also develops, manufactures, markets, and sells products that increase the chance of successful transplants by facilitating a match between a donor and a recipient of stem cells and organs. It sells Olerup SSP, which is used to type human leukocyte antigen (HLA) alleles based on sequence-specific primer technology; Olerup SBT, a product range for sequence-based typing of HLA alleles; QTYPE that enables speed and precision in HLA typing at a low to intermediate resolution for samples that require a fast turn-around-time and uses real-time polymerase chain reaction methodology; and TruSight HLA, a high resolution solution that uses next generation sequencing methodology. The company offers its products directly to customers, as well as through third-party distributors and sub-distributors. It has a license agreement with Illumina for the development, commercialization, and distribution of next generation sequencing product line for use in transplantation diagnostic testing. The company was formerly known as XDx, Inc. and changed its name to CareDx, Inc. in March 2014. CareDx, Inc. was incorporated in 1998 and is headquartered in Brisbane, California.
Company Analysis and Financial Data Status
| Data | Last Updated (UTC time) |
|---|---|
| Company Analysis | 2020/02/17 00:41 |
| End of Day Share Price | 2020/02/14 00:00 |
| Earnings | 2019/09/30 |
| Annual Earnings | 2018/12/31 |
Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more here.